A bispecific antibody that is capable of specifically binding to an epitope within the KPI-2 domain of tissue factor pathway inhibitor (TFPI) and an epitope within the KPI-3 domain of TFPI, wherein the heavy chain that binds to KPI-2 comprises • a CDR1 sequence corresponding to amino acid residues 31 to 35 of SEQ ID NO: 3; • a CDR2 sequence corresponding to amino acid residues 50 to 66 of a sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 5 and SEQ ID NO: 7; • a CDR3 sequence corresponding to amino acid residues 99 to 110 of SEQ ID NO: 3; wherein the light chain that binds to KPI-2 comprises • a CDR1 sequence corresponding to amino acid residues 24 to 39 of SEQ ID NO: 4; • a CDR2 sequence corresponding to amino acid residues 55 to 61 of SEQ ID NO: 4; a CDR3 sequence corresponding to amino acid residues 94 to 102 of SEQ ID NO: 4; wherein the heavy chain that binds to KPI-3 comprises • a CDR1 sequence corresponding to amino acid residues 31 to 35 of SEQ ID NO: 9; • a CDR2 sequence corresponding to amino acid residues 50 to 66 of SEQ ID NO: 9; • a CDR3 sequence corresponding to amino acid residues 99 to 107 of SEQ ID NO: 9; and wherein the light chain that binds to KPI-3 comprises • a CDR1 sequence corresponding to amino acid residues 24 to 34 of SEQ ID NO: 10; • a CDR2 sequence corresponding to amino acid residues 50 to 56 of SEQ ID NO: 10; a CDR3 sequence corresponding to amino acid residues 89 to 97 of SEQ ID NO: 10. wherein the heavy chain that binds to KPI-2 comprises • a CDR1 sequence corresponding to amino acid residues 31 to 35 of SEQ ID NO: 3; • a CDR2 sequence corresponding to amino acid residues 50 to 66 of a sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 5 and SEQ ID NO: 7; • a CDR3 sequence corresponding to amino acid residues 99 to 110 of SEQ ID NO: 3; • a CDR1 sequence corresponding to amino acid residues 31 to 35 of SEQ ID NO: 3; • a CDR2 sequence corresponding to amino acid residues 50 to 66 of a sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 5 and SEQ ID NO: 7; • a CDR3 sequence corresponding to amino acid residues 99 to 110 of SEQ ID NO: 3; wherein the light chain that binds to KPI-2 comprises • a CDR1 sequence corresponding to amino acid residues 24 to 39 of SEQ ID NO: 4; • a CDR2 sequence corresponding to amino acid residues 55 to 61 of SEQ ID NO: 4; a CDR3 sequence corresponding to amino acid residues 94 to 102 of SEQ ID NO: 4; • a CDR1 sequence corresponding to amino acid residues 24 to 39 of SEQ ID NO: 4; • a CDR2 sequence corresponding to amino acid residues 55 to 61 of SEQ ID NO: 4; a CDR3 sequence corresponding to amino acid residues 94 to 102 of SEQ ID NO: 4; wherein the heavy chain that binds to KPI-3 comprises • a CDR1 sequence corresponding to amino acid residues 31 to 35 of SEQ ID NO: 9; • a CDR2 sequence corresponding to amino acid residues 50 to 66 of SEQ ID NO: 9; • a CDR3 sequence corresponding to amino acid residues 99 to 107 of SEQ ID NO: 9; • a CDR1 sequence corresponding to amino acid residues 31 to 35 of SEQ ID NO: 9; • a CDR2 sequence corresponding to amino acid residues 50 to 66 of SEQ ID NO: 9; • a CDR3 sequence corresponding to amino acid residues 99 to 107 of SEQ ID NO: 9; and wherein the light chain that binds to KPI-3 comprises • a CDR1 sequence corresponding to amino acid residues 24 to 34 of SEQ ID NO: 10; • a CDR2 sequence corresponding to amino acid residues 50 to 56 of SEQ ID NO: 10; a CDR3 sequence corresponding to amino acid residues 89 to 97 of SEQ ID NO: 10. • a CDR1 sequence corresponding to amino acid residues 24 to 34 of SEQ ID NO: 10; • a CDR2 sequence corresponding to amino acid residues 50 to 56 of SEQ ID NO: 10; a CDR3 sequence corresponding to amino acid residues 89 to 97 of SEQ ID NO: 10. <EOS>